Tag:
Cerezyme
Latest Headlines
Latest Headlines
Pfizer aims at Genzyme with Gaucher drug approval
In announcing the FDA approval of its new Gaucher disease treatment Elelyso, Pfizer put Genzyme firmly in its sights.
FDA OK for Gaucher drug opens new market for Pfizer, Protalix
After initially being rebuffed at the FDA Pfizer and Protalix have snagged an FDA OK for their new Gaucher disease drug Elelyso (taliglucerase).
Shire to boost Vpriv, Replagal with EMA-approved plant
Shire 's rare-disease challenge is heating up.
Genzyme wins key FDA approval for new plant
You can bet that Sanofi's ( $SNY ) top brass are celebrating this evening. The French drugmaker's Genzyme unit won the long-sought FDA approval for its new plant in Framingham, MA. That facility can
No consolation for Sanofi as Genzyme scrambles
Genzyme's ongoing manufacturing problems certainly vindicate Sanofi's skepticism during merger talks earlier this year. And supply constraints affecting key Genzyme drugs mean Sanofi ( $SNY ) didn't
Genzyme's Gaucher treatment runs short again
Genzyme has another supply problem to confess. The rare-disease specialist, acquired by Sanofi ( $SNY ) earlier this year, said its Cerezyme drug for Gaucher disease would run short beginning next
Shire: Safe to switch from Genzyme meds to Replagal, Vpriv
Shire unveiled top-line data from new studies suggesting it's safe for Fabry disease patients to switch to Replagal from Genzyme's Fabrazyme, which has been running scarce for some time. In addition,
Genzyme pays back $6M jobs incentive
Genzyme, technically falling short of job-creation goals set by Massachusetts in an incentives package, has repaid the state $6 million. Spokesperson Erin Emlock says in an email the company created
Cerezyme departs drug-shortage list; BMS injection joins
Genzyme has come roaring out of the 2011 GMP-comeback gate by stabilizing the supply of Gaucher disease treatment Cerezyme and eliminating restrictions on its use. "We can now provide Cerezyme as
Genzyme ($GENZ) swats first consent decree pitch
Genzyme ($GENZ) last week beat an end-of-November deadline for one action item dictated by its manufacturing consent decree with the FDA announced last May. It has moved the fill/finish operations of
